ID   MK06_HUMAN              Reviewed;         721 AA.
AC   Q16659; B2R945; B5BU65; Q68DH4; Q8IYN8;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 197.
DE   RecName: Full=Mitogen-activated protein kinase 6;
DE            Short=MAP kinase 6;
DE            Short=MAPK 6;
DE            EC=2.7.11.24;
DE   AltName: Full=Extracellular signal-regulated kinase 3;
DE            Short=ERK-3;
DE   AltName: Full=MAP kinase isoform p97;
DE            Short=p97-MAPK;
GN   Name=MAPK6; Synonyms=ERK3, PRKM6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal skeletal muscle;
RX   PubMed=7969157; DOI=10.1128/mcb.14.12.8202-8211.1994;
RA   Zhu A.X., Zhao Y., Moller D.E., Flier J.S.;
RT   "Cloning and characterization of p97MAPK, a novel human homolog of rat ERK-
RT   3.";
RL   Mol. Cell. Biol. 14:8202-8211(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Smooth muscle;
RX   PubMed=8875998;
RA   Meloche S., Beatty B.G., Pellerin J.;
RT   "Primary structure, expression and chromosomal locus of a human homolog of
RT   rat ERK3.";
RL   Oncogene 13:1575-1579(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Oral cancer;
RA   Saranath D., Mahale A., Rai R., Dedhia P.;
RT   "ERK-3 cDNA clone isolated from human oral cancer.";
RL   Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Esophageal carcinoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-290.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   UBIQUITINATION AT MET-1.
RX   PubMed=15226418; DOI=10.1128/mcb.24.14.6140-6150.2004;
RA   Coulombe P., Rodier G., Bonneil E., Thibault P., Meloche S.;
RT   "N-Terminal ubiquitination of extracellular signal-regulated kinase 3 and
RT   p21 directs their degradation by the proteasome.";
RL   Mol. Cell. Biol. 24:6140-6150(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION AT SER-189.
RX   PubMed=21177870; DOI=10.1074/jbc.m110.181529;
RA   Deleris P., Trost M., Topisirovic I., Tanguay P.L., Borden K.L.,
RA   Thibault P., Meloche S.;
RT   "Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated
RT   kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5
RT   signaling pathway.";
RL   J. Biol. Chem. 286:6470-6478(2011).
RN   [13]
RP   INTERACTION WITH UBE3A AND NEURL4.
RX   PubMed=22645313; DOI=10.1128/mcb.00201-12;
RA   Martinez-Noel G., Galligan J.T., Sowa M.E., Arndt V., Overton T.M.,
RA   Harper J.W., Howley P.M.;
RT   "Identification and proteomic analysis of distinct UBE3A/E6AP protein
RT   complexes.";
RL   Mol. Cell. Biol. 32:3095-3106(2012).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-386; SER-452;
RP   SER-556; SER-558; SER-665 AND SER-684, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-290.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Atypical MAPK protein. Phosphorylates microtubule-associated
CC       protein 2 (MAP2) and MAPKAPK5. The precise role of the complex formed
CC       with MAPKAPK5 is still unclear, but the complex follows a complex set
CC       of phosphorylation events: upon interaction with atypical MAPKAPK5,
CC       ERK3/MAPK6 is phosphorylated at Ser-189 and then mediates
CC       phosphorylation and activation of MAPKAPK5, which in turn
CC       phosphorylates ERK3/MAPK6. May promote entry in the cell cycle (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation at Ser-189.
CC   -!- SUBUNIT: Heterodimer with ERK4/MAPK4. Interacts with (via FRIEDE motif)
CC       MAPKAPK5 (By similarity). Interacts with UBE3A; this interaction may be
CC       indirect and mediated by HERC2, possibly via HERC2 interaction with
CC       NEURL4. {ECO:0000250, ECO:0000269|PubMed:22645313}.
CC   -!- INTERACTION:
CC       Q16659; Q9GZV1: ANKRD2; NbExp=7; IntAct=EBI-1384105, EBI-12111292;
CC       Q16659; Q9H6Z9: EGLN3; NbExp=6; IntAct=EBI-1384105, EBI-1175354;
CC       Q16659; Q8IW41: MAPKAPK5; NbExp=9; IntAct=EBI-1384105, EBI-1201460;
CC       Q16659; Q8IW41-2: MAPKAPK5; NbExp=6; IntAct=EBI-1384105, EBI-11958803;
CC       Q16659; P12504: vif; Xeno; NbExp=2; IntAct=EBI-1384105, EBI-779991;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC       Note=Translocates to the cytoplasm following interaction with MAPKAPK5.
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highest expression in the skeletal muscle, followed
CC       by the brain. Also found in heart, placenta, lung, liver, pancreas,
CC       kidney and skin fibroblasts.
CC   -!- DOMAIN: In contrast to classical MAPKs, the TXY motif within the
CC       activation loop is replaced by the SEG motif, whose phosphorylation
CC       activates the MAP kinases. {ECO:0000250}.
CC   -!- PTM: Phosphorylated at Ser-189 by PAK1, PAK2 and PAK3 resulting in
CC       catalytic activation. Phosphorylated by MAPKAPK5 at other sites.
CC       {ECO:0000269|PubMed:21177870}.
CC   -!- PTM: Ubiquitination at Met-1 leads to degradation by the proteasome
CC       pathway. {ECO:0000269|PubMed:15226418}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK6ID43349ch15q21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X80692; CAA56709.1; -; mRNA.
DR   EMBL; L77964; AAA98769.1; -; mRNA.
DR   EMBL; AF420474; AAL17605.1; -; mRNA.
DR   EMBL; AK313633; BAG36392.1; -; mRNA.
DR   EMBL; CR749401; CAH18246.1; -; mRNA.
DR   EMBL; AB451301; BAG70115.1; -; mRNA.
DR   EMBL; BC035492; AAH35492.1; -; mRNA.
DR   CCDS; CCDS10147.1; -.
DR   PIR; A56352; A56352.
DR   RefSeq; NP_002739.1; NM_002748.3.
DR   RefSeq; XP_005254594.1; XM_005254537.2.
DR   RefSeq; XP_005254595.1; XM_005254538.2.
DR   RefSeq; XP_005254596.1; XM_005254539.3.
DR   RefSeq; XP_011520084.1; XM_011521782.1.
DR   PDB; 6YKY; X-ray; 2.52 A; A/B/C/D=9-327.
DR   PDB; 6YLC; X-ray; 2.43 A; A/B/C/D=9-327.
DR   PDB; 6YLL; X-ray; 2.89 A; A/B=9-327.
DR   PDB; 7AQB; X-ray; 2.25 A; A/B=9-327.
DR   PDBsum; 6YKY; -.
DR   PDBsum; 6YLC; -.
DR   PDBsum; 6YLL; -.
DR   PDBsum; 7AQB; -.
DR   AlphaFoldDB; Q16659; -.
DR   SMR; Q16659; -.
DR   BioGRID; 111583; 454.
DR   CORUM; Q16659; -.
DR   IntAct; Q16659; 403.
DR   MINT; Q16659; -.
DR   STRING; 9606.ENSP00000261845; -.
DR   BindingDB; Q16659; -.
DR   ChEMBL; CHEMBL5121; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB01017; Minocycline.
DR   DrugCentral; Q16659; -.
DR   MoonDB; Q16659; Predicted.
DR   iPTMnet; Q16659; -.
DR   PhosphoSitePlus; Q16659; -.
DR   BioMuta; MAPK6; -.
DR   DMDM; 2499596; -.
DR   CPTAC; CPTAC-885; -.
DR   CPTAC; CPTAC-886; -.
DR   EPD; Q16659; -.
DR   jPOST; Q16659; -.
DR   MassIVE; Q16659; -.
DR   MaxQB; Q16659; -.
DR   PaxDb; Q16659; -.
DR   PeptideAtlas; Q16659; -.
DR   PRIDE; Q16659; -.
DR   ProteomicsDB; 61018; -.
DR   Antibodypedia; 3920; 567 antibodies from 38 providers.
DR   DNASU; 5597; -.
DR   Ensembl; ENST00000261845.7; ENSP00000261845.5; ENSG00000069956.14.
DR   Ensembl; ENST00000680066.1; ENSP00000505862.1; ENSG00000069956.14.
DR   Ensembl; ENST00000680652.1; ENSP00000506184.1; ENSG00000069956.14.
DR   Ensembl; ENST00000680777.1; ENSP00000505601.1; ENSG00000069956.14.
DR   Ensembl; ENST00000681888.1; ENSP00000506036.1; ENSG00000069956.14.
DR   Ensembl; ENST00000691380.1; ENSP00000509662.1; ENSG00000069956.14.
DR   GeneID; 5597; -.
DR   KEGG; hsa:5597; -.
DR   MANE-Select; ENST00000261845.7; ENSP00000261845.5; NM_002748.4; NP_002739.1.
DR   UCSC; uc002abp.4; human.
DR   CTD; 5597; -.
DR   DisGeNET; 5597; -.
DR   GeneCards; MAPK6; -.
DR   HGNC; HGNC:6879; MAPK6.
DR   HPA; ENSG00000069956; Low tissue specificity.
DR   MIM; 602904; gene.
DR   neXtProt; NX_Q16659; -.
DR   OpenTargets; ENSG00000069956; -.
DR   PharmGKB; PA30624; -.
DR   VEuPathDB; HostDB:ENSG00000069956; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   GeneTree; ENSGT00940000154351; -.
DR   HOGENOM; CLU_000288_181_15_1; -.
DR   InParanoid; Q16659; -.
DR   OMA; EADWQLH; -.
DR   OrthoDB; 741207at2759; -.
DR   PhylomeDB; Q16659; -.
DR   TreeFam; TF105098; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   PathwayCommons; Q16659; -.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   SignaLink; Q16659; -.
DR   SIGNOR; Q16659; -.
DR   BioGRID-ORCS; 5597; 27 hits in 1074 CRISPR screens.
DR   ChiTaRS; MAPK6; human.
DR   EvolutionaryTrace; Q16659; -.
DR   GeneWiki; MAPK6; -.
DR   GenomeRNAi; 5597; -.
DR   Pharos; Q16659; Tbio.
DR   PRO; PR:Q16659; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q16659; protein.
DR   Bgee; ENSG00000069956; Expressed in cartilage tissue and 213 other tissues.
DR   Genevisible; Q16659; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0032156; C:septin cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004707; F:MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR008350; MAPK_ERK3/4.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01771; ERK3ERK4MAPK.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cytoplasm; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..721
FT                   /note="Mitogen-activated protein kinase 6"
FT                   /id="PRO_0000186257"
FT   DOMAIN          20..316
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          701..721
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           189..191
FT                   /note="SEG motif"
FT   MOTIF           332..337
FT                   /note="FRIEDE motif"
FT   ACT_SITE        152
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         26..34
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         49
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         189
FT                   /note="Phosphoserine; by PAK1, PAK2 and PAK3"
FT                   /evidence="ECO:0000269|PubMed:21177870,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         386
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         556
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         558
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         665
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         684
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        1
FT                   /note="Peptide (Met-Gly) (interchain with G-Cter in
FT                   ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:15226418"
FT   VARIANT         290
FT                   /note="L -> V (in dbSNP:rs35697691)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042256"
FT   CONFLICT        229
FT                   /note="K -> R (in Ref. 4; BAG36392)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        527
FT                   /note="F -> L (in Ref. 4; BAG70115)"
FT                   /evidence="ECO:0000305"
FT   STRAND          14..16
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   TURN            17..19
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          20..25
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          34..39
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   TURN            40..42
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          45..52
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           56..70
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          80..84
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          86..88
FT                   /evidence="ECO:0007829|PDB:6YLC"
FT   STRAND          102..109
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          112..114
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           115..120
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           126..145
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:6YLC"
FT   HELIX           155..157
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          158..161
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   TURN            162..165
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          166..169
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          174..176
FT                   /evidence="ECO:0007829|PDB:6YLC"
FT   HELIX           180..182
FT                   /evidence="ECO:0007829|PDB:6YLC"
FT   TURN            183..186
FT                   /evidence="ECO:0007829|PDB:6YKY"
FT   HELIX           190..192
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           200..204
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           211..227
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           237..247
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           253..260
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           265..270
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          271..273
FT                   /evidence="ECO:0007829|PDB:6YLL"
FT   HELIX           278..281
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   STRAND          282..285
FT                   /evidence="ECO:0007829|PDB:6YLC"
FT   HELIX           287..294
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           301..303
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           307..312
FT                   /evidence="ECO:0007829|PDB:7AQB"
FT   HELIX           314..317
FT                   /evidence="ECO:0007829|PDB:7AQB"
SQ   SEQUENCE   721 AA;  82681 MW;  DAA3AAA9B98BB31F CRC64;
     MAEKFESLMN IHGFDLGSRY MDLKPLGCGG NGLVFSAVDN DCDKRVAIKK IVLTDPQSVK
     HALREIKIIR RLDHDNIVKV FEILGPSGSQ LTDDVGSLTE LNSVYIVQEY METDLANVLE
     QGPLLEEHAR LFMYQLLRGL KYIHSANVLH RDLKPANLFI NTEDLVLKIG DFGLARIMDP
     HYSHKGHLSE GLVTKWYRSP RLLLSPNNYT KAIDMWAAGC IFAEMLTGKT LFAGAHELEQ
     MQLILESIPV VHEEDRQELL SVIPVYIRND MTEPHKPLTQ LLPGISREAL DFLEQILTFS
     PMDRLTAEEA LSHPYMSIYS FPMDEPISSH PFHIEDEVDD ILLMDETHSH IYNWERYHDC
     QFSEHDWPVH NNFDIDEVQL DPRALSDVTD EEEVQVDPRK YLDGDREKYL EDPAFDTNYS
     TEPCWQYSDH HENKYCDLEC SHTCNYKTRS SSYLDNLVWR ESEVNHYYEP KLIIDLSNWK
     EQSKEKSDKK GKSKCERNGL VKAQIALEEA SQQLAGKERE KNQGFDFDSF IAGTIQLSSQ
     HEPTDVVDKL NDLNSSVSQL ELKSLISKSV SQEKQEKGMA NLAQLEALYQ SSWDSQFVSG
     GEDCFFINQF CEVRKDEQVE KENTYTSYLD KFFSRKEDTE MLETEPVEDG KLGERGHEEG
     FLNNSGEFLF NKQLESIGIP QFHSPVGSPL KSIQATLTPS AMKSSPQIPH QTYSSILKHL
     N
//
